2. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global cancer observatory: cancer today; 2020 [Internet]. Lyon: International Agency for Research on Cancer; c2023 [cited 2023 Nov 3]. Available from:
https://gco.iarc.who.int/today.
5. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-84.
6. Darragh TM, Colgan TJ, Thomas Cox J, Heller DS, Henry MR, Luff RD, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 2013;32:76-115.
10. Lim S, Lee MJ, Cho I, Hong R, Lim SC. Efficacy of p16 and Ki-67 immunostaining in the detection of squamous intraepithelial lesions in a high-risk HPV group. Oncol Lett 2016;11:1447-52.
11. Miralpeix E, Solé-Sedeño JM, Mancebo G, Lloveras B, Bellosillo B, Carreras R, et al. Value of p16(INK4a) and Ki-67 immunohistochemical staining in cervical intraepithelial neoplasia grade 2 biopsies as biomarkers for cervical intraepithelial neoplasia grade 3 in cone results. Anal Quant Cytopathol Histpathol 2016;38:1-8.
12. Silva DC, Gonçalves AK, Cobucci RN, Mendonça RC, Lima PH, Cavalcanti G Júnior. Immunohistochemical expression of p16, Ki-67 and p53 in cervical lesions - a systematic review. Pathol Res Pract 2017;213:723-9.
15. Singh P, Kaushik S, Thakur B, Acharya S, Bhardwaj A, Bahal N. Evaluation of variable p16 immunostaining patterns, Ki-67 indices and HPV status in cervical SILs and squamous cell carcinomas: an institutional experience. Indian J Pathol Microbiol 2023;66:63-9.
17. WHO Classification of Tumours Editorial Board. Female genital tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2020.
18. Kurman RJ, Carcangiu ML, Herrington S, Young RH. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: IARC; 2014.
20. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2013;17:S1-27.
23. Clinton LK, Miyazaki K, Ayabe A, Davis J, Tauchi-Nishi P, Shimizu D. The LAST guidelines in clinical practice: implementing recommendations for p16 use. Am J Clin Pathol 2015;144:844-9.
24. Thrall MJ. Effect of lower anogenital squamous terminology recommendations on the use of p16 immunohistochemistry and the proportion of high-grade diagnoses in cervical biopsy specimens. Am J Clin Pathol 2016;145:524-30.
27. da Costa LBE, Triglia RM, Andrade LALA. p16INK4a, cytokeratin 7, and Ki-67 as potential markers for low-grade cervical intraepithelial neoplasia progression. J Low Genit Tract Dis 2017;21:171-6.
31. Mazurec K, Trzeszcz M, Mazurec M, Streb J, Halon A, Jach R. Should we use risk selection tests for HPV 16 and/or 18 positive cases: comparison of p16/Ki67 and cytology. J Med Virol 2024;96:e29500.
32. Shalaby NA, Tudorescu-Morjan C, Manole CG, Iacata AA, Popovici ML, Grecu LI, et al. Correlation between high-risk HPV infection and p16/Ki-67 abnormalities in Pap samples in a South Eastern Europe cohort. J Med Virol 2024;96:e29524.
33. Sepodes B, Rebelo T, Santos F, Oliveira D, Catalão C, Águas F, et al. Optimization of HPV-positive women triage with p16/Ki67 dual staining cytology in an organized cervical cancer screening program in the center region of Portugal. Eur J Obstet Gynecol Reprod Biol 2024;302:111-5.